[go: up one dir, main page]

CA3104513A1 - Implants pour la liberation de substances pharmaceutiques lipophiles ou amphiphiles - Google Patents

Implants pour la liberation de substances pharmaceutiques lipophiles ou amphiphiles Download PDF

Info

Publication number
CA3104513A1
CA3104513A1 CA3104513A CA3104513A CA3104513A1 CA 3104513 A1 CA3104513 A1 CA 3104513A1 CA 3104513 A CA3104513 A CA 3104513A CA 3104513 A CA3104513 A CA 3104513A CA 3104513 A1 CA3104513 A1 CA 3104513A1
Authority
CA
Canada
Prior art keywords
implant
pharmaceutical substance
excipient
implants
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104513A
Other languages
English (en)
Inventor
Rajesh A. Patel
Sunil Sreedharan
Benjamin FURMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Titan Pharmaceuticals Inc
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Publication of CA3104513A1 publication Critical patent/CA3104513A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des implants qui comprennent des substances pharmaceutiques lipophiles. Les excipients qui sont utilisés fournissent une libération appropriée et réglable/ajustable du médicament lipophile à partir de la matrice de l'implant. Les implants peuvent être implantés chez un patient pour libérer les substances pharmaceutiques. L'invention concerne également des procédés de fabrication et des méthodes d'utilisation de tels implants.
CA3104513A 2018-06-25 2019-06-25 Implants pour la liberation de substances pharmaceutiques lipophiles ou amphiphiles Pending CA3104513A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689735P 2018-06-25 2018-06-25
US62/689,735 2018-06-25
PCT/US2019/039072 WO2020006000A1 (fr) 2018-06-25 2019-06-25 Implants pour la libération de substances pharmaceutiques lipophiles ou amphiphiles

Publications (1)

Publication Number Publication Date
CA3104513A1 true CA3104513A1 (fr) 2020-01-02

Family

ID=68985992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104513A Pending CA3104513A1 (fr) 2018-06-25 2019-06-25 Implants pour la liberation de substances pharmaceutiques lipophiles ou amphiphiles

Country Status (8)

Country Link
US (1) US20210113664A1 (fr)
EP (1) EP3810173A4 (fr)
JP (2) JP2021529747A (fr)
CN (1) CN112638400A (fr)
AU (1) AU2019294615A1 (fr)
CA (1) CA3104513A1 (fr)
MX (1) MX2020014160A (fr)
WO (1) WO2020006000A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020012458A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2022231930A1 (fr) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
WO2024167829A1 (fr) * 2023-02-09 2024-08-15 Celanese Eva Performance Polymers Llc Dispositif implantable pour la libération d'un agoniste du récepteur du peptide-1 de type glucagon
WO2025174767A1 (fr) * 2024-02-13 2025-08-21 Biraj Investments, Llc Dispositifs implantables très chargés ayant une résistance à la traction élevée pour l'administration de médicament

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
IL164152A0 (en) * 2002-03-26 2005-12-18 Teva Pharma Drug microparticles
WO2005082277A1 (fr) * 2004-02-18 2005-09-09 Stanford University Systemes d'administration de medicaments utilisant des films d'oxyde mesoporeux
CA2568641A1 (fr) * 2004-05-31 2005-12-15 Smart Drug Systems Inc Composition a liberation prolongee
CA2548881A1 (fr) * 2005-05-27 2006-11-27 University Of Ottawa Matrice de biopolymere et de neoglycopolymere reticules
MX2008012264A (es) * 2006-03-24 2009-02-20 Auxilium Int Holdings Inc Composiciones estabilizadas que contienen farmacos labiles alcalinos.
CN101511380B (zh) * 2006-07-11 2012-12-12 昌达生物科技公司 用于持续释放递送肽的药物组合物
ITMI20061539A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
ES2533359T3 (es) * 2007-09-07 2015-04-09 Mati Therapeutics Inc. Núcleos de fármaco para liberación sostenida de agentes terapéuticos
ES2441550T3 (es) * 2007-12-21 2014-02-05 Ludwig-Maximilians-Universität Dispositivos extruidos con forma de varilla para la Iiberación controlada de sustancias biológicas a humanos y animales
ES2689420T3 (es) * 2008-03-31 2018-11-14 Nitto Denko Corporation Sistema de administración de permeante y métodos para su uso
WO2009158412A2 (fr) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Libération lente d'exenatide et autres polypeptides
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
BRPI1007318A2 (pt) * 2009-01-23 2019-04-09 Qlt Inc. distribuição com liberação sustentada de um ou mais agentes.
AR075846A1 (es) * 2009-03-17 2011-04-27 Organon Nv Sistema de administracion de farmaco de lactona macrociclica.uso. metodo de tratamiento
US20120034306A1 (en) * 2009-04-17 2012-02-09 Pollock Wayne C Polymeric drug delivery systems and processes for producing such systems
US20110144591A1 (en) * 2009-12-11 2011-06-16 Ross Russell F Transdermal Delivery Device
US20120283624A1 (en) * 2011-05-05 2012-11-08 Gary Bradford Shirley Drug Eluting Device and Method of Use Thereof
WO2014059245A1 (fr) * 2012-10-11 2014-04-17 Tufts University Compositions et procédés pour l'administration prolongée d'agents thérapeutiques tels que des agonistes du récepteur glp-1
JP6882186B2 (ja) * 2014-12-15 2021-06-02 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法
GB2545880A (en) * 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
CN105963257B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
WO2018064556A1 (fr) * 2016-09-29 2018-04-05 Gesea Biosciences Inc. Implant bioérodable pour l'administration de médicament à long terme et procédés de fabrication et d'utilisation associés
US10988442B2 (en) * 2016-11-09 2021-04-27 Novomedix, Llc Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use

Also Published As

Publication number Publication date
AU2019294615A1 (en) 2021-02-11
MX2020014160A (es) 2021-03-09
JP2025069303A (ja) 2025-04-30
EP3810173A4 (fr) 2022-03-30
US20210113664A1 (en) 2021-04-22
CN112638400A (zh) 2021-04-09
JP2021529747A (ja) 2021-11-04
EP3810173A1 (fr) 2021-04-28
WO2020006000A1 (fr) 2020-01-02

Similar Documents

Publication Publication Date Title
US20240189224A1 (en) Implantable devices for drug delivery with reduced burst release
US20210113664A1 (en) Implants for release of lipophilic or amphiphilic pharmaceutical substances
KR101914119B1 (ko) 약물 전달용 이종 이식가능 장치
US20180098934A1 (en) Mucoadhesive devices for delivery of active agents
US20210177742A1 (en) Loadable porous structures for use as implants
CA3014864C (fr) Preparation contenant de l'esomeprazole
HK40005962B (en) Implantable devices for drug delivery with reduced burst release
HK40005962A (en) Implantable devices for drug delivery with reduced burst release
JP2004331500A (ja) 血中濃度制御製剤
Patiwala et al. Recent trends in sustained release oral drug delivery system: A promising approach
TWI426929B (zh) 持續性釋放之含抗生素醫藥組合物、製備法及其應用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928